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ttp://dx.doi.org/10.1016/j.ajpath.2012.10.007Hindgut-derived endoderm can differentiate into rectal, prostatic, and bladder phenotypes. Stromal-
epithelial interactions are crucial for this development; however, the precise mechanisms by which
epithelium responds to stromal cues remain unknown. We have previously reported ectopic expression of
peroxisome proliferator-activated receptor-g2 (PPARg2) increased androgen receptor expression and
promoted differentiation of mouse prostate epithelium. PPARg is also implicated in urothelial differ-
entiation. Herein we demonstrate that knockdown of PPARg2 in benign human prostate epithelial cells
(BHPrEs) promotes urothelial transdifferentiation. Furthermore, in vitro and in vivo heterotypic tissue
regeneration models with embryonic bladder mesenchyme promoted urothelial differentiation of
PPARg2-deﬁcient BHPrE cells, and deﬁciency of both PPARg isoforms 1 and 2 arrested differentiation.
Because PTEN deﬁciency is cooperative in urothelial pathogenesis, we engineered BHPrE cells with
combined knockdown of PPARg and PTEN and performed heterotypic recombination experiments using
embryonic bladder mesenchyme. Whereas PTEN deﬁciency alone induced latent squamous differentiation
in BHPrE cells, combined PPARg and PTEN deﬁciency accelerated the development of keratinizing
squamous metaplasia (KSM). We further conﬁrmed via immunohistochemistry that gene expression
changes in metaplastic recombinants reﬂected human urothelium undergoing KSM. In summary, these
data suggest that PPARg isoform expression provides a molecular basis for observations that adult human
epithelium can be transdifferentiated on the basis of heterotypic mesenchymal induction. These
data also implicate PPARg and PTEN inactivation in the development of KSM. (Am J Pathol 2013, 182:
449e459; http://dx.doi.org/10.1016/j.ajpath.2012.10.007)Supported by grants from the NIH, National Institute of Diabetes and
Digestive and Kidney Diseases (1P20 DK090874-01 and 2R01 DK067049
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D.W.S. and D.J.D. contributed equally to this work.Bidirectional communication between epithelial and stromal
tissue compartments is essential for normal organ develop-
ment and tissue differentiation. In the context of develop-
mental biology, mesenchyme has been historically classiﬁed
as having the ability to act in either a permissive or
instructive manner.1 Permissive mesenchyme enables the
epithelium to follow a default preprogramed developmental
fate, and instructive mesenchyme induces the epithelium to
adopt an alternative developmental fate. The ability of
mesenchyme to act either permissively or instructively is
often tested through implementation of tissue recombination
experiments, which can be homotypic (matched mesen-
chyme and epithelium) or heterotypic.2 Landmark tissuestigative Pathology.
.recombination studies using embryonic urogenital sinus
mesenchyme (UGM) and either embryonic urogenital
epithelium or adult bladder urothelium have demonstrated
that the urothelium could be instructed to form prostate-like
Strand et alacini.3e7 Studies have also shown that prostatic differenti-
ation is dependent on expression of a functional androgen
receptor (AR) in the stromal compartment.8
Although important discoveries have been made insofar
as the molecular program required for prostate development
and differentiation, insights into epithelial and stromal
factors important for bladder development and urothelial
differentiation have been generally lacking. The identiﬁca-
tion of pathways important for normal bladder development
and urothelial differentiation has important implications for
developmental biology, tissue regeneration, and malig-
nancy.9,10 Recent studies have identiﬁed speciﬁc molecular
pathways in normal bladder development and urothelial
response to injury; however, tissue regeneration using
genetically manipulated epithelial and stromal components
has rarely been applied to determine their importance in
bladder development.
The peroxisome proliferator-activated receptor-g (PPARg)
and phosphatase and tensin homologue deleted on chromo-
some ten (PTEN) pathways are important modulators of
cellular energy balance that have been implicated repeatedly
in urothelial and prostate differentiation and malignancy.
PPARg is expressed as two isoforms, which are tissue
speciﬁc.11 PTEN is commonly lost or mutated in prostate
and bladder disease,12,13 which suggests that it has an
important role in the maintenance of differentiation. When
combined with inhibition of epidermal growth factor
receptor, a pathway repressed by PTEN, the PPARg agonist
troglitazone is associated with increased expression of
markers of urothelial differentiation in normal human uro-
thelial cells.14 An understanding of PPARg activity in uro-
thelial differentiation is potentially important clinically
because use of the PPARg agonist pioglitazone is associated
with an increased risk of bladder cancer.15 These studies
strongly identiﬁed PPARg as an important regulator of the
urothelial phenotype but warrant a deeper understanding of
the molecular control.14e20 Inactivation of PTEN has also
been implicated in the development of bladder cancer and
seems to cooperate with other important genetic changes to
drive tumorigenesis.21,22
The objective of the present study was to determine the
importance of PPARg isoforms and PTEN activity in
urogenital differentiation. We adapted three-dimensional
(3D) co-culture and in vivo tissue regeneration models
using a benign human prostate epithelial cell line (BHPrE)
that expresses both PPARg isoforms and regenerates
CK14þ/CK18þ/ARþ prostate tissue in vivo,23 Knockdown
experiments demonstrated that PPARg2 is essential for
induction of prostate epithelial differentiation by urogeni-
tal mesenchyme and that PPARg2-deﬁcient prostate epi-
thelium can be induced by fetal bladder mesenchyme to
transdifferentiate into urothelium. Knockdown of both
PPARg isoforms 1 and 2 arrested even urothelial differen-
tiation of BHPrE cells. Furthermore, we demonstrated that
tissue regeneration of PTEN-deﬁcient BHPrE cells induced
focal metaplasia and hyperplasia at 3 months, followed by450squamous metaplasia at 6 months. Deﬁciency of both PTEN
and PPARg1/2 cooperated to drive keratinizing squamous
metaplasia (KSM) by 3 months, which exhibited a similar
deregulation of genes implicated in human KSM. In sum-
mary, we used novel tissue regeneration models with ge-
netically manipulated human prostate epithelial cells to
reproduce and characterize differentiation to urothelial and
KSM phenotypes.
Materials and Methods
Cell Line Generation
Control, PPARg1/2, and PPARg2eshRNA cell lines were
generated using the following constructs (Figure 1A), gener-
ously provided by Dr. Vishna Chatterjee (Metabolic Research
Laboratories, Cambridge, UK): sequence R2 (50-AACTCT-
GGGAGATTCTCCA-30) is PPARg2-speciﬁc, and sequence
R1 (50-GAAGACATTCCATTCACAA-30) corresponds to a
region present in both PPARg1 and PPARg2 isoforms, and
both sequences are identical inmouse andhuman receptors.The
Scramble II shRNAsequence (Dharmacon, Inc., Lafayette,CO)
was used as negative control (CTRLsh). Retroviral constructs
were generated by cloning double-stranded oligonucleotides
(Sigma-Aldrich, St. Louis, MO) encoding these sequences
together with a hairpin (italicized) into the BamHI/EcoRI sites
of pSIREN-RetroQ (BD Biosciences, San Jose, CA): pS-R1,
(50-GATCCCCGAAGACATTCCATTCACAATTCAAGA-
GATTGTGAATGGAATGTCTTCTTTTTGGAAA-30 and
50-AATTTTTCCAAAAAGAAGACATTCCATTCACAAT-
CTCTTGAATTGTGAATGGAATGTCTTCGGG-30); pS-R2,
(50-GATCCCCAACTCTGGGAGATTCTCCA-TTCAAGA-
GAAGGAGAATCTCCCAGAGTTTTTTTGGAAA-30 and
50-AATTTTTCCAAAAAAACTCTGGGAGATTCTCCA-
TCTCTTGAAAGGAGAATCTCCCAGAGT-TGGG-30); and
pS-CTRLsh, (50-GATCCCCGAAGACATTCCATTCACAA-
TTCAAGAGATTTTTTTGGAAA-30 and 50-AATTTTTCCAA-
AAAATCTCTTGAATTGTGAATGGAATGTCTTCGGG-30).
Production of retroviruses and generation of BHPrE stable
cell lines was performed as recommended by the manufac-
turer. Stable cell lines were cultured in normal growth
medium supplemented with puromycin to sustain shRNA
expression.
LacZ control and four different PTEN shRNAs were
generated as described,24 using the Invitrogen BLOCK-iT
Inducible H1 RNAi Entry Vector Kit (Life Technologies
Corp., Carlsbad, CA). After stable selection, the strongest
PTEN down-regulation was achieved with the following
PTEN sense and anti-sense strands: 50-CACCGATTTA-
GGCTTGACTTATAACGTGTGCTGTCCGTTATAGGT-
CAAGTCTAAGTC-30 and 50-AAAAGACTTAGACTTGA-
CCTATAACGGACAGCACACGTTATAAGTCAAGCCT-
AAATC-30. Packaging vector and control or PTEN shRNA
vectors cloned into a lentiviral expression plasmid (pLenti6/
BLOCK-iT-DEST; Life Technologies) were co-transfected
into 293FT packaging cells with Lipofectamine 2000ajp.amjpathol.org - The American Journal of Pathology
Figure 1 PPARg2 deﬁciency in BHPrE cell lines induces permissive urothelial transdifferentiation in vitro. A: Alignment of the N-terminal regions of mouse
(m) and human (h) PPARg, with location of the sequences targeted by shRNAs. Tissue regeneration with BHPrEPPARg2sh cells and rUGM induced focal metaplasia
characteristic of urothelium (Uro?), with increased p63 (B) and decreased AR (C). D: Western blot analysis of control versus PPARg2 knockdown in BHPrE cells
revealed increased p63 and urothelial marker CK20 but decreased prostate marker AR; knockdown of PPARg1/2 displayed low AR and no increase in CK20. Dual
immunoﬂuorescence with CK14 (basal marker) and CK8/18 (luminal marker) revealed a signiﬁcant decrease in luminal cells (CK8/18þ) in PPARg2 knockdown
versus control BHPrE cells (E versus F, quantiﬁed in G), with a trending but nonsigniﬁcant increase in CK14þ basal cells. *P< 0.05.
PPARg and PTEN Deﬁciency and KSM(Life Technologies) for lentiviral production. Control,
PPARg1/2-, and PPARg2-deﬁcient cell lines were
then infected with LacZ (control) or PTEN shRNA lenti-
virus, followed by stable selection with blasticidin to gen-
erate dual knockdown cell lines (BHPrECTRLsh:LacZsh,
BHPrECTRLsh:PTENsh, BHPrEPPARg1/2sh:LacZsh, BHPrEPPARg1/2
sh:PTENsh, BHPrEPPARg2sh:LacZsh, and BHPrEPPARg2sh:PTENsh).
3D Co-Culture and Tissue Regeneration
Three dimentional Cultrex overlay co-culture was per-
formed as described previously.25 In brief, mesenchymal
cells from either 18-day embryonic rat urogenital sinus
mesenchyme (rUGM) or 16-day embryonic rat bladder
mesenchyme (rBM) were dissociated into single cells using
collagenase digestion. Coverslips were coated with 50 mL
Cultrex, and BHPrE control and PPARg2sh cells were
seeded alone or in co-culture with rUGM or rBM at a ratioThe American Journal of Pathology - ajp.amjpathol.orgof 1:2.5 and overlaid with 2% Cultrex. Media were changed
every 3 days, and cultures were grown for 8 days. Immu-
nocytochemistry was performed as described previously.
Cells were ﬁxed using 3.7% formaldehyde at room
temperature and permeabilized using 0.2% Triton X-100
in PBS for 5 minutes. Then cells were washed three times
with PBS-glycine (130 mmol/L NaCl, 7 mmol/L NaHPO4,
3.5 mmol/L NaH2PO4, and 100 mmol/L glycine) and
blocked for 1 hour by incubating with an immunoﬂuores-
cence buffer (130 mmol/L NaCl, 7 mmol/L NaHPO4, 3.5
mmol/L NaH2PO4, 7.7 mmol/L NaN3, 0.1% bovine serum
albumin, 0.2% Triton X-100, 0.05% Tween 20, and 10%
goat serum). In controls, preimmune rabbit or mouse IgG
replaced primary antibodies. The cells were double-labeled
using antibodies to CK14 (1:50; Vector Laboratories,
Inc., Burlingame, CA) and AR (1:40; Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA) or CK14 and asymmetric unit
membraneepan-uroplakin (UP; 1:500; a generous gift from451
Strand et alDr. Xue-Ru Wu, New York University) and incubated
overnight, followed by incubation for 1 hour at room
temperature using ﬂuorescence-labeled secondary antibody.
Cells were then washed and imaged using a water immer-
sion lens on a confocal microscope (LSM 510 META NLO;
Carl Zeiss GmbH, Jena, Germany).
Tissue regeneration was performed as described previ-
ously.23,26 In brief, rUGM from 18-day-old fetal rat pups
and rBM from 16-day-old fetal rat pups were dissected and
recombined with epithelium for grafting under the renal
capsule in nude mice for 3 months. All grafts were repeated
a minimum of three times, and results varied insofar as the
severity of the phenotypes, as is expected in these types of
regenerative studies.
The human origin of cells in tissue recombinants was
conﬁrmed via PCR of genomic DNA isolated from scrap-
ings taken from parafﬁn-embedded sections on glass slides
(Supplemental Figure S1) using the following previously
validated species-speciﬁc primers and PCR conditions: human
prostate-speciﬁc antigen (374 bp), forward, 50-GATGACTC-
CAGCCACGACCT-30, and reverse, 50-CCTTCTGAGGG-
TGAACTTGC-30; mouse probasin (302 bp), forward,
50-TCACATTTTGTGTGGGAGGA-30, and reverse, 50-CAT-
ATAATCACAACCCATCTCTTGA-30; rat probasin (420 bp),
forward, 50-TTGAAGGGAATGGAGAACC-30, and re-
verse, 50-CATCCCTCCAGCCCTATCTA-30. PCR was
performed using 40 cycles at 94C for 45 seconds, 58C for
45 seconds, and 68C for 1 minute 30 seconds.
Western Blot Analysis
Western blot analysis was performed as described previ-
ously.27 In brief, 40 mg total protein was loaded onto 10%
polyacrylamide gels (Life Technologies) and transferred
onto nitrocellulose (PerkinElmer, Inc., Waltham, MA). Blots
were subsequently blocked in 5% bovine serum albumin
in Tris-buffered saline solution and Tween 20 and probed
using the following antibodies: CK20 (1:200; Abcam PLC,
Cambridge, MA); CK14 (1:500; Vector Laboratories);
b-actin (1:2000; Sigma-Aldrich); p63 (1:500), AR (1:500),
and PPARg (1:250); all three from Santa Cruz Bio-
technology); E-cadherin (1:500; BD Transduction Labora-
tories, BD Biosciences); and PTEN (1:1000), Akt (1:1000),
pAkt (S473) (1:1000), pERK (1:1000), and cyclin D1
(1:1000); all ﬁve from Cell Signaling Technology, Inc.
(Danvers, MA).
Tissue Acquisition and Immunostaining
Deidentiﬁed human bladder tissue samples were obtained
from the Translational Pathology Shared Resources Core at
the Vanderbilt Ingram Cancer Center in accordance with
Vanderbilt University Institutional Review Board protocols.
Presence of KSMwas veriﬁed via pathologic examination by
an author (J.M.M.C.). For immunoﬂuorescence, cells in
culture were dual immunostained and counted as described452previously.27 Results were statistically analyzed using
Student’s unpaired t-test using Prism software (GraphPad
Prism 4 Software, Inc., La Jolla, CA). In brief, cells were
grown to 70% conﬂuence and ﬁxed in 4% paraformaldehyde
for 15 minutes, washed, and probed using the following
antibodies at 4C overnight: CK8/18 (1:2000; Fitzgerald
Industries International, Acton, MA), CK14 (1:250;
Vector Laboratories), and PPARg (1:25; Santa Cruz
Biotechnology).
For immunohistochemistry, sections were processed as
described previously.27 In brief, sections were deparafﬁnized
in Histoclear and rehydrated, and endogenous peroxidases
were blocked using methanol. After 1 hour of blocking with
5% serum, sections were incubated at 4C overnight with the
following antibodies: PPARg (1:25), AR (1:200), p63
(1:200), and FOXA1 (1:1000); all four from Santa Cruz
Biotechnology); E-cadherin (1:1000; BD Transduction
Laboratories); pAkt (S473) (1:25) and pERK (1:500); both
from Cell Signaling Technology); CK10 (1:500); DakoCy-
tomation; Dako North America, Inc., Carpinteria, CA);
CK14 (1:500; Vector Laboratories), and human asymmetric
unit membraneepan-UP (1:10,000).
Results
PPARg2 Deﬁciency in BHPrE Cell Lines Induces
Permissive Urothelial Transdifferentiation in Vitro
PPARg1/2 knockdown in mouse prostate epithelium induces
autophagy and high-grade prostatic intraepithelial neoplasia
both in conditional knockout (KO) transgenic mice and in
tissue regeneration studies using inductive UGM.28,29 In
addition, rescue with PPARg2 in PPARgKO mouse prostate
epithelial cells drives AR expression and function.27 These
data suggest that PPARg2 may be an isoform-speciﬁc fa-
ctor important for prostatic differentiation. To determine the
effects of PPARg2 isoform deﬁciency on human pro-
state epithelium, we generated shRNAs to PPARg1/2 or
PPARg2 alone (Figure 1A) and stable knockdown cell lines
using a BHPrE cell line that we had previously estab-
lished.23 We performed tissue regeneration studies using
inductive urogenital mesenchyme (rUGM) and either
BHPrE control scrambled shRNA knockdown
(BHPrECTRLsh) or PPARg2 knockdown (BHPrEPPARg2sh)
cell lines. BHPrECTRLsh plus rUGM regenerated prostate
structures similar to those previously described (data not
shown).23 Areas of focal metaplasia in BHPrEPPARg2sh
recombinants were observed. Some of these areas were
composed of a thickened p63þ AR epithelium with
morphologic features reminiscent of urothelium (Figure 1, B
and C).
p63 expression is normally limited to basal cells of prostate
epithelium and to basal and intermediate human bladder
urothelial cells.9,30 Western blot analysis revealed that,
compared with BHPrECTRLsh cells, BHPrEPPARg2sh cells
in vitro expressed increased p63 and the superﬁcial urothelialajp.amjpathol.org - The American Journal of Pathology
Figure 2 PPARg2 deﬁciency in BHPrE cell lines induces permissive urothelial transdifferentiation in a 3D model of homotypic and heterotypic mesenchyma
tissue recombination. BHPrE control cells recombined with either UGM (AeC) or bladder mesenchyme (BM) (DeF) form ARþ/CK14þ/UP structures. PPARg2-
deﬁcient BHPrE cells recombined with UGM (GeI) or BM (JeL) form AR/CK14þ/UPþ structures. Insets in B, E, I and L are enlarged regions of interest. Scale
bars: 90 mm for differential interference contrast images and 45.18 mm for velocity images.
PPARg and PTEN Deﬁciency and KSM(umbrella cell) marker CK20 (Figure 1D). Furthermore,
knockdown of both PPARg1 and PPARg2 (BHPrEPPARg1/2sh)
showed reduced AR and absence of CK20, which suggested
inhibition of both prostate luminal and urothelial umbrella cell
differentiation. Dual immunoﬂuorescence revealed that most
BHPrECTRLsh cells in culture expressed PPARg1/2 (data not
shown) and that subpopulations were positive for the basal and
luminal epithelial markers CK14 or CK8/18, respectively
(Figure 1E). In BHPrEPPARg2sh cells, there was a slight inc-
rease in CK14þ cells and a substantial decrease in CK8/18þ
cells (Figure 1, F and G). These data suggest that our pooledThe American Journal of Pathology - ajp.amjpathol.orgepithelial cell lines have additional cellular subtypes in addition
to CK14/p63þ and CK18/20þ cells that may support cellular
differentiation in a PPARg-dependent manner. PPARg1/2-
deﬁcient cells expressed low levels of all differentiation
markers examined,which suggests the possibility that PPARg1
is necessary for both prostate and urothelial differentiation.
Previous studies have demonstrated the developmental
plasticity of hindgut-derived epithelium in response to various
mesenchyma.4,5,7 To determine whether PPARg2-deﬁcient
human prostate epitheliumwas responsive to induction by fetal
bladder mesenchyme, we adapted a novel in vitro 3D Cultrex453
Figure 3 PPARg2 deﬁciency in BHPrE cell lines induces permissive urothelial transdifferentiation, whereas PPARg1/2 deﬁciency arrests urothelial
differentiation in an in vivo model of heterotypic mesenchyma tissue recombination. Control BHPrE cells recombined with bladder mesenchyme regenerate
poorly differentiated structures negative for AR or UP (AeD), whereas PPARg2-deﬁcient BHPrE cells regenerate focal UPþ structures (EeH). PPARg1 and
PPARg2 deﬁciency in BHPrE cells results in arrest of urothelial differentiation and prostatic differentiation demonstrated by AR and UP structures that were
positive only for CK14 (IeL). Scale bars: 50 mm.
Strand et aloverlay co-culture system25 in which dissociated cells from
inductive fetal urogenital or bladder mesenchyme were plated
under Cultrex-embedded epithelium and grown for 8 days.
As expected from previous tissue recombination studies
performed in vivo,23 homotypic co-culture of rUGM with
BHPrECTRLsh prostate epithelium regenerated luminized
ARþ glandular epithelium surrounded by CK14þ basal cells
(Figure 2, AeC). Predominantly ARþ acini were observed
in BHPrECTRLsh co-cultures with rBM as well (Figure 2,
DeF). However, BHPrEPPARg2sh epithelium co-cultured with
either rBM (Figure 2, GeI) or rUGM (Figure 2, JeL) regen-
erated UPþ cells in approximately 40% of the epithelial
structures, which suggested that PPARg2 is necessary for
differentiation of prostatic epithelium after co-culture with
inductive mesenchyme.
To determine whether PPARg isoform-deﬁciency was
associated with urothelial transdifferentiation in vivo, we re-
combined inductive bladder mesenchyme with BHPrECTRLsh,
BHPrEPPARg1/2sh or BHPrEPPARg2sh cells, followed by xeno-
grafting into the renal capsule of immunocompromised mice
for tissue regeneration. Similar to results from the heterotypic
3D co-culture model, we observed regeneration of AR/UPþ
urothelial structureswithBHPrEPPARg2sh cells (Figure 3,EeH)
but not BHPrECTRLsh cells (Figure 3, AeD). Bladder mesen-
chyme recombination with BHPrEPPARg1/2sh cells regenerated
poorly differentiated CK14þ/AR/UP acini (Figure 3, IeL),
indicating that PPARg1 is minimally required for regeneration
of differentiated urothelium.454PTEN Deﬁciency in BHPrE Cells Drives Epithelial
Hyperplasia and Late Squamous Differentiation in Vivo
PTEN loss has been implicated in bladder and prostate
diseases and cooperates with multiple other mutations
to drive pathologic changes.21,22,31e34 To determine the
effect of PTEN deﬁciency on regeneration of an human
prostate epithelial cell line capable of urothelial trans-
differentiation (Figures 2 and 3), BHPrE cells were stably
transfected with PTEN shRNA, recombined using either
bladder or urogenital mesenchyme and regenerated
under the renal capsule of immunocompromised mice.
At 3 months after grafting, tissue recombinants of
BHPrEPTENsh cells with either heterotypic bladder
mesenchyme (Figure 4, AeE) or homotypic urogenital
mesenchyme (Figure 4, FeJ) contained epithelial struc-
tures that were positive for pAkt (Figure 4, E and J)
and resembled either prostate (Figure 4, C and H) or
urothelium (Figure 4, D and L), sometimes within the
same gland (Figure 4, C and D). Hyperplastic areas in
UGM-containing recombinations showed decreased AR
expression (Figure 4H) at 3 months. Six-month bladder
mesenchyme recombinants progressed to a CK10þ/
CK14þ/AR/UP squamous phenotype (Figure 4, KeO).
Of note, expression of the urothelial superﬁcial cell marker
CK20 was observed only in PTEN-deﬁcient recombinants
with heterotypic bladder mesenchyme (Supplemental
Figure S2, AeC).ajp.amjpathol.org - The American Journal of Pathology
Figure 4 PTEN deﬁciency in BHPrE cells drives epithelial hyperplasia and late squamous differentiation in vivo. PTEN-deﬁcient BHPrE cells recombined with
bladder mesenchyme (BM) drives focal urothelial metaplasia (UPþ) and Akt phosphorylation (AeE), whereas recombination with UGM causes hyperplasia alone
(FeJ). Long-term tissue recombinants develop squamous metaplasia characterized by acquisition of CK10 immunoreactivity (inset in L versus insets in B and
G) and loss of late-stage differentiation markers of prostate or urothelium (Supplemental Figure S1C). KeO: Recombination with bladder mesenchyme. Scale
bars: 100 mm (A, B, F, K, and L); 50 mm (C-E, G-J, and M); 20 mm (N, O, and all insets).
PPARg and PTEN Deﬁciency and KSMDual PPARg1/2 and PTEN Deﬁciency Promotes KSM
in Vivo After Recombination With Bladder Mesenchyme
To determine whether PTEN and PPARg deﬁciency cooperate
to negatively affect differentiation status,BHPrEPPARg1/2sh and
BHPrEPPARg2sh cell lines were each stably transfected with
PTEN shRNA and recombined with inductive bladder
mesenchyme for tissue regeneration. Double knockdown
of PTEN and PPARg2 regenerated UPþ urothelial struc-
tures, similar to PPARg2 deﬁciency alone (data not shown).
However, combined deﬁciency of PPARg1/2 and PTEN
resulted in KSM at 3 months after grafting (Figure 5, AeH).
Similar to long-term BHPrEPTENsh grafts (Figure 4, KeO),
BHPrEPTENsh/PPARg1/2 structures were positive for the squa-
mous markers CK10 (Figure 5B) and CK14 (not shown) and
negative for uroplakin (Figure 5D), nuclear PPARg
(Figure 5G), and the PPARg-regulated urogenital differentia-
tion transcription factor FOXA114 (Figure 5C), previously
demonstrated to be lost in premalignant KSM lesions and
squamous cell carcinoma (SCC) of the bladder.26 FOXA1
expression was not lost in BHPrECTRLsh, BHPrEPTENsh or
BHPrEPPARg2sh cells (Supplemental FigureS2,DeF).Western
blot analysis of known downstream targets of PPARg and
PTEN including pERK1/2,35 E-cadherin,36 cyclin D137, and
pAKT38 demonstrated that even with low PTEN expression,
PPARg1/2 deﬁciency inhibited the activation ofAKT,whereas
other signaling pathways such as ERK1/2 were still activated
(Figure 5I). Of note, PPARg1/2 deﬁciency alone similarly
resulted in decreased PTEN expression but was not associated
with increased AKT phosphorylation or cyclin D1 levels. We
also noted that decreased expression of PPARg1/2 or PPARg2
alone resulted in increased expression of basal cell markers
(CK14 and p63), which was diminished when combined withThe American Journal of Pathology - ajp.amjpathol.orgPTEN deﬁciency. Furthermore, PTEN deﬁciency was corre-
lated with E-cadherin loss in vitro.
Wepreviously generated amouse prostate epithelial cell line
with genetic ablation ofPPARg that contained a 5%population
of CK14þ basal cells (mPrE-PPARgKO) induced by rUGM to
form hyperplastic ARþ prostatic acini.29 Rescue withPPARg2
drove an increased percentage of basal cells and increased
differentiation of luminal cells through AR expression and
function.27 To determine whether PTEN deﬁciency also
induced squamous differentiation of mouse prostate epithe-
lium, we generated a stable derivative of mPrE-PPARgKO
cells with PTEN knockdown, which resulted in increased
expression of basal cell markers including p63 (Supplemental
Figure S3A). When recombined with rUGM for 6 weeks,
mPrE-gKOPTENsh cells regenerated a squamous epithelium
(p63þ/CK10þ/CK14þ/FOXA1) (Supplemental Figure S3B)
similar to that observed in long-term BHPrEPTENsh (Figure 4,
KeO) and short-term BHPrEPTENsh/PPARg1/2 (Figure 5AeH)
tissue regeneration experiments.
To conﬁrmwhether PPARg and PTEN signaling pathways
were similarly disrupted in human keratinizing squamous
urothelial metaplasia, we performed immunohistochemistry
on human cystectomy samples with histopathologically
conﬁrmed KSM for the same proteins analyzed in our human
cell line model. We ﬁrst conﬁrmed the presence of squamous
differentiation (Figure 5L) and the loss of the urothelial
differentiation markers FOXA1 (Figure 5M) and uroplakin
(Figure 5N). We were also able to conﬁrm cytoplasmic
PPARg (Figure 5Q), low pAKT (Figure 5R), and increased
pERK (Figure 5O); however, E-cadherin (Figure 5P) immu-
noreactivity was higher than anticipated on the basis of
Western blot protein levels in the human cell line model.
Similar molecular effects were demonstrated in long-term455
Figure 5 Dual PPARg1/2 and PTEN deﬁciency in BHPrE cells recapitulates human KSM in vivo. A: Western blot analysis of BHPrE cell lines revealed that
PTEN deﬁciency increased phosphorylation of ERK1/2 and decreased E-cadherin but increased AKT phosphorylation (and downstream cyclin D1 expression) only
in the presence of PPARg1 and PPARg2. Furthermore, knockdown of both PPARg1 and PPARg2 decreased PTEN expression and slightly increased CK14 and p63,
whereas knockdown of PPARg2 alone dramatically increased CK14 and p63. B: Diagram of the phenotypic consequence of knockdown of PTEN, PPARg1/2, or
PPARg2 individually or coordinately in BHPrE cells after recombination with bladder mesenchyme. CeJ: Dual deﬁciency of PTEN and PPARg1/2 in BHPrE cells
drove KSM 3 months after xenografting with bladder mesenchyme, characterized by gain of CK10 (D) and loss of FOXA1 (E) and UP (F); arrows indicate internal
control areas. Furthermore, pERK (G) was strongly activated, whereas pAKT was only weakly expressed (J), and in the limited number of cells in which PPARg
was expressed, it was localized to the cytoplasm (I). Human KSM samples were immunostained for the same markers and showed similar patterns of expression
including gain of CK10 (L) and loss of FOXA1 (M) and UP (N), with internal controls showing ureter (insets). Furthermore, ERK (O) and AKT (R) were similarly
activated as in the human cell line model, and PPARg expression was similarly cytoplasmic (Q). Scale bars: 100 mm (A); 50 mm (B-G, K, and M-O); 20 mm (H, L,
P-R, and all insets).
Strand et alsquamous BHPrEPTENsh grafts, in which FOXA1 was
lost, pERK was activated, and PPARg was cytoplasmic
(Supplemental Figure S3C). In summary, we have demon-
strated the ability to transdifferentiate human prostate
epithelium into urothelium through down-regulation of
PPARg2, whereas depletion of both PPARg isoforms
causes decreased differentiation of either cell type. Further-
more, induction of squamous differentiation by PTEN is456accelerated through combined PPARg1/2 deﬁciency, which
was corroborated in human KSM of the bladder (Figure 5J).
Discussion
The data presented herein suggest a role for the regulation of
epithelial cellular metabolism in the process of differentia-
tion. We have presented a human tissue regeneration modelajp.amjpathol.org - The American Journal of Pathology
PPARg and PTEN Deﬁciency and KSMof urothelial transdifferentiation and KSM of human pros-
tate epithelial cells deﬁcient in both PPARg and PTEN.
These data extend observations about the plasticity of
hindgut epithelia after heterotypic recombination with em-
bryonic mesenchyma4,5,7 by suggesting that expression
of PPARg2 and PTEN is required for maintenance of
a prostate epithelial phenotype. Herein we have provided
evidence that PPARg2 expression is important for mesen-
chymal induction of prostate epithelial differentiation
because down-regulation of PPARg2 resulted in increased
expression of urothelial markers in 3D (Figure 2) and
in vivo (Figure 3) tissue regeneration experiments after
recombination with either urogenital or bladder mesen-
chyme. These data support our previous observations that
ectopic PPARg2 expression in a PPARgKO mouse prostate
epithelial cell line promotes differentiation, potentially
through a switch from glucose to fatty acid metabolism.27
We have also demonstrated that knockdown of both
PPARg1 and PPARg2 prohibited induction of urothelial
differentiation by bladder mesenchyme, which suggests that
PPARg1 is minimally necessary for urothelial trans-
differentiation and that PPARg2 is not. Knockdown of both
PTEN and PPARg1/2 in BHPrE cells recombined with
bladder mesenchyme resulted in regeneration of KSM.
Metaplastic conversion of human urothelium to a squamous
phenotype can be either nonkeratinizing or keratinizing, and
this distinction has important clinical ramiﬁcations. Whereas
non-KSM is common in female patients and tends to develop
in the bladder neck or trigone (trigonitis), KSM is a recog-
nized precursor to development of SCC of the bladder.39
Understanding the molecular events that result in the
development of KSM and subsequently SCC is important
because this subtype of bladder cancer is particularly
aggressive. Immunohistochemical analysis of human tissue
acquired from patients with deﬁnitive KSM revealed cyto-
plasmic PPARg expression and increased ERK activation,
indicating knockdown of PTEN and PPARg1/2 in BHPrE
with subsequent recombination with bladder mesenchyme is
capable of modeling this metaplastic event. This conclusion
is further supported by immunohistochemical analysis that
revealed the presence of E-cadherin and pAKT, and absence
of FOXA1, which was previously reported in human
KSM.26 These results indicate that this system recapitulates
important molecular events in the development of KSM.
This is important because a diagnosis of SCC of the bladder
is predictive of poor prognosis in patients with bladder
cancer. Biochemical analysis revealed that PTEN deﬁciency
induced AKT activation only in the presence of PPARg1,
whereas ERK activation downstream of PTEN deﬁciency
was independent of either PPARg isoform expression
(Figure 5I). These observations are interesting for many
reasons. First, they suggest that PPARg isoforms are
important regulators of PI3K/AKT signaling in premalignant
KSM. Second, these results suggest that patients with KSM
and/or SCC of the bladder may be particularly suited to
MAPK pathway inhibition. This is especially interestingThe American Journal of Pathology - ajp.amjpathol.orginasmuch as local recurrence is the primary cause of death in
patients receiving treatment of pure SCC of the bladder,40
and increased squamous component may increase the like-
lihood of local recurrence after radical cystectomy.41 Using
human KSM tissue, we were able to conﬁrm the molecular
characteristics observed in our human tissue regeneration
model by showing increased activated ERK and a decrease
in activated AKT signaling.
The role of PTEN loss in SCC is interesting because PTEN
inactivation is associatedwith SCC at several anatomical sites
including the head and neck,42 esophagus43, and cervix44, and
with basal carcinomas of the breast.45 Pure SCC constitutes
approximately 5% of all bladder cancers, whereas 90% of
bladder cancers are histologically characterized as urothelial
cell carcinomas. Although PTEN inactivation has previously
been implicated in urothelial cell carcinomas, our ﬁnding that
PTEN inactivation cooperates with decreased PPARg
signaling to drive metaplastic conversion of urothelium to
a squamous phenotype is important because little is known
about the molecular mechanisms that mediate the develop-
ment of KSM and SCC. Our observations need not be limited
to KSM and SCC of the bladder because most urothelial cell
carcinomas also exhibit some degree of squamous differen-
tiation, and tumors of the upper urinary tract can exhibit
mixed or pure squamous histologic features. In summary, we
have demonstrated through novel adaptations of in vitro and
in vivo tissue recombination and regeneration studies that
prostate epithelium can be transdifferentiated into urothelium
on the basis of suppression of PPARg2 (Figures 1 and 2),
which can be further transformed into a keratinizing squa-
mous phenotype via decreased PPARg1 and PTEN (Figure 4
and Figure 5, AeJ). Moreover, these results mimicked KSM
of human bladder (Figure 5, KeR) and suggested that loss
of PPARg and PTEN may drive proliferation by activation
of ERK.
Beyond the speciﬁc experimental end points, these
observations enable us to speculate about important points
relative to cellular differentiation and disease. First, although
mesenchymal cells have long been known to drive speciﬁc
developmental outcomes, the molecular details by which
these ends are achieved have not been well understood.
Paracrine acting factors that regulate cellular proliferation
have been implicated as stromal-epithelial mediators. The
observations presented herein are consistent with the idea
that such factors could modulate epithelial gene expression,
resulting in metabolic changes that affect differentiation.
These observations also suggest the possibility that systemic
changes in nutritional status might contribute to the desta-
bilization of differentiation, perhaps altering epithelial me-
tabolism contributing to disease-related changes in cell or
tissue structure. The stochastic nature of the changes ob-
served, with parts of structures or subpopulations of 3D
cultures being affected, also play into the focal nature of
some disease entities including some malignant tumors, as
well as focal benign conditions such as benign hyperplasia.
Future work should focus on development of increased457
Strand et alunderstanding of the pathways that drive metaplastic con-
version and/or squamous differentiation of urothelial cell
carcinoma, with the objective of identifying novel thera-
peutic approaches.Acknowledgments
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